A Phase II Randomized, Double-blind, Placebo-controlled, Multi-center Study of Finite Therapy of TAF in Combination With PEG-IFN and Hepalatide in Subjects With Chronic Hepatitis B
Latest Information Update: 01 Dec 2021
Price :
$35 *
At a glance
- Drugs Hepalatide (Primary) ; Peginterferon alfa-2a (Primary) ; Tenofovir alafenamide (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Shanghai HEP Pharmaceutical
- 01 Dec 2021 New trial record